Biomarkers & Beyond: LabConnect’s Role in Oncology Research

Blood is the currency of clinical trials—and getting it from patient to lab within 48 hours can make or break a study. In this episode, LabConnect CEO Wes Wheeler joins us to discuss how a lab-agnostic model, purpose-built software, and disciplined process design are transforming global clinical research.

Wes breaks down why LabConnect chooses not to own labs and how this decision enables speed, scale, and flexibility across seven key regions where trials are conducted and patients reside. He also unpacks the technology powering their connected ecosystem—unified LIMS, ERP, sample tracking, and data integrations that convert scattered specialty testing into submission-ready data. The result: a network that supports roughly 80% of the data used in new drug applications, while preserving audit trails and regulatory integrity for agencies like the FDA and EMA.

Looking ahead, Wes explores how AI, machine learning, and digital twins are reshaping clinical development—from modeling preclinical safety to identifying recruitable patient populations and flagging anomalies before they impact results. With cell and gene therapies, antibody-drug conjugates, and radiopharma driving the next wave of precision medicine, he shares how LabConnect’s innovation mindset keep trials moving forward.

Along the way, Wes reflects on the mentorship, engineering mindset, and leadership lessons that took him from mechanical engineer to global healthcare executive.

Collaborate with us!

Support the show

For more information about the innovations that are shaping tomorrow's world, head to https://tomorrowsworldtoday.com/

To keep up-to-date with the latest in innovation, technology, sustainability, and more connect with us on social:
YouTube
Instagram
Facebook
Twitter
LinkedIn